Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Lisata Therapeutics ( (LSTA) ) is now available.
On January 20–21, 2026, Lisata Therapeutics announced it had entered into a binding term sheet with privately held Kuva Labs for a negotiated acquisition via an all‑cash tender offer of $4.00 per share, to be followed by a short‑form merger, with Lisata stockholders also eligible for two non‑tradeable contingent value rights worth up to an additional $2.00 per share upon achieving specified certepetide‑related milestones. The offer, unanimously approved by both companies’ boards and expected to be formalized in a definitive purchase agreement before February 27, 2026, represents roughly an 85% premium to Lisata’s most recent closing price, or about 180% including the CVRs, and is structured with exclusivity, standstill and break‑up fee provisions that protect both parties while allowing Lisata to consider superior competing bids; the deal underscores the strategic value Kuva sees in Lisata’s certepetide‑based oncology platform and could deliver a substantial liquidity event for shareholders if the tender offer and subsequent merger close as planned.
The most recent analyst rating on (LSTA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.
Spark’s Take on LSTA Stock
According to Spark, TipRanks’ AI Analyst, LSTA is a Neutral.
The score is held down primarily by weak financial performance (tiny revenue base, large losses, and ongoing cash burn) and bearish technicals (below key moving averages with negative MACD). Offsetting factors include a debt-free balance sheet and a more constructive earnings update featuring expense reductions, a cash runway into early 2027, and positive clinical/partnership milestones, though Phase III funding needs remain a key risk.
To see Spark’s full report on LSTA stock, click here.
More about Lisata Therapeutics
Lisata Therapeutics, based in Basking Ridge, N.J., is a clinical‑stage pharmaceutical company focused on discovering, developing and commercializing innovative therapies for advanced solid tumors and other serious diseases. Its lead cyclic peptide candidate, certepetide (formerly LSTA1), is designed to activate a tumor‑specific uptake pathway to improve penetration and effectiveness of co‑administered or tethered anti‑cancer drugs, and has received multiple U.S. and EU regulatory designations, including Fast Track and Orphan Drug status in several oncology indications. Lisata leverages its CendR Platform technology through commercial and R&D partnerships and is advancing a pipeline of programs it expects to fund into early 2027.
Average Trading Volume: 69,862
Technical Sentiment Signal: Strong Sell
Current Market Cap: $19.05M
For detailed information about LSTA stock, go to TipRanks’ Stock Analysis page.